Melqart Asset Management (Uk) LTD Biomarin Pharmaceutical Inc Transaction History

Melqart Asset Management (Uk) LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$74.43 - $92.22 $12.9 Million - $15.9 Million	172,949 New	172,949 $14.2 Million
Q3 2022 Nov 14, 2022	SELL	$82.16 - $96.94 $904,745 - $1.07 Million	-11,012 Reduced 6.6%	155,849 $13.2 Million
Q2 2022 Aug 15, 2022	SELL	$71.48 - $86.85 $11.7 Million - $14.2 Million	-163,401 Reduced 49.48%	166,861 $13.8 Million
Q1 2022 May 16, 2022	SELL	$74.28 - $92.69 $12.9 Million - $16.1 Million	-173,357 Reduced 34.42%	330,262 $25.5 Million
Q4 2021 Feb 14, 2022	SELL	$71.72 - $91.47 $7.11 Million - $9.07 Million	-99,181 Reduced 16.45%	503,619 $44.5 Million
Q3 2021 Nov 15, 2021	BUY	$74.77 - $85.47 $11.4 Million - $13 Million	152,000 Added 33.72%	602,800 $46.6 Million
Q2 2021 Aug 16, 2021	BUY	$75.51 - $84.79 $9.29 Million - $10.4 Million	123,000 Added 37.52%	450,800 $37.6 Million
Q1 2021 May 17, 2021	BUY	$74.73 - $90.69 $24.5 Million - $29.7 Million	327,800 New	327,800 $24.8 Million

635

178M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $11.8B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Melqart Asset Management (Uk) LTD, based on Form 13F filings with the SEC.

Stay updated on Melqart Asset Management (Uk) LTD with notifications on news.